

Initial Prior Authorization

Testosterone – Testosterone Enanthate

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name	Dosage Form
testosterone enanthate (generic Delatestryl – brand unavailable)	testosterone enanthate	injection
Xyosted	testosterone enanthate	injection

Indications

FDA-approved Indications

Testosterone Enanthate Injection

Males

Testosterone enanthate injection (generic Delatestryl) is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.

Primary hypogonadism (congenital or acquired) - Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchiectomy.

Hypogonadotropic hypogonadism (congenital or acquired) - Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance).

If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will

be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty.

Safety and efficacy of testosterone enanthate injection (generic Delatestryl) in men with age-related hypogonadism have not been established.

Delayed puberty - Testosterone enanthate injection (generic Delatestryl) may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers.

Females

Metastatic mammary cancer - Testosterone enanthate injection (generic Delatestryl) may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or anti-estrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.

Xyosted

Xyosted (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the low or normal range.

Limitations of Use:

- Safety and efficacy of Xyosted in males less than 18 years old have not been established.

Coverage Criteria

Breast Cancer (Hormone-Responsive Tumor)

Authorization may be granted when the requested drug is being prescribed for a premenopausal patient with breast cancer who has benefited from oophorectomy AND is considered to have a hormone-responsive tumor when ALL of the following criteria are met:

- The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism). [NOTE: Safety and efficacy of testosterone products in patients with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.]
- The request is for intramuscular testosterone enanthate injection (generic Delatestryl).

Delayed Puberty

Authorization may be granted when the requested drug is being prescribed for delayed puberty when ALL of the following criteria are met:

- The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism). [NOTE: Safety and efficacy of testosterone products in patients with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.]
- The request is for intramuscular testosterone enanthate injection (generic Delatestryl).

Inoperable Metastatic Breast Cancer

Authorization may be granted when the requested drug is being prescribed for inoperable metastatic breast cancer in a patient who is 1 to 5 years postmenopausal AND had an incomplete response to other therapy for metastatic breast cancer when ALL of the following criteria are met:

- The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism). [NOTE: Safety and efficacy of testosterone products in patients with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.]
- The request is for intramuscular testosterone enanthate injection (generic Delatestryl).

Primary or Hypogonadotropic Hypogonadism

Authorization may be granted when the requested drug is being prescribed for primary or hypogonadotropic hypogonadism when ALL of the following criteria are met:

- The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism). [NOTE: Safety and efficacy of testosterone products in patients with

Reference number(s)
906-A

“age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.]

- Before the start of testosterone therapy, the patient has at least TWO confirmed low morning testosterone levels according to current practice guidelines or your standard lab reference values.

Continuation of Therapy

Breast Cancer (Hormone-Responsive Tumor), Delayed Puberty, Inoperable Metastatic Breast Cancer

All patients (including new patients) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section.

Primary or Hypogonadotropic Hypogonadism

Authorization may be granted when the requested drug is being prescribed for primary or hypogonadotropic hypogonadism when ALL of the following criteria are met:

- The requested drug is NOT being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism). [NOTE: Safety and efficacy of testosterone products in patients with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.]
- Before the patient started testosterone therapy, the patient had a confirmed low morning testosterone level according to current practice guidelines or your standard lab reference values.

Duration of Approval (DOA)

- 906-A: DOA: 12 months

References

1. Testosterone Enanthate [package insert]. E. Windsor, NJ: Eugia US LLC; February 2024.
2. Xyosted [package insert]. Ewing, NJ: Antares Pharma, Inc.; August 2023.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 3, 2025.

4. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 3, 2025.
5. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/03/2025).
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

Document History

Written by: UM Development (AP)

Date: 02/2002

Revised: (MG) 02/2003; (NB) 01/2005; (MG) 02/2006; (NB) 02/2007(2); (AM) 01/2008, 12/2008; (MS) 11/2009, 11/2010; (TM) 11/2011, 10/2012 (extended duration); (PL) 11/2012, 11/2013; (SE) 04/2014 (rephrased diagnosis question); (CF/JH) 11/2014, 02/2015 (updated testosterone level question); (LN) 04/2015 (added denial reasons); (CF/JH) 11/2015; (SE) 06/2016 (created separate Med D); (CF/JH) 11/2016; (KC) 11/2017, 10/2018 (added Xyosted), 10/2018, 08/2019 (removed "male" from lab questions), 10/2019 (removed MDC from title), 02/2020 (no clinical changes), 02/2021 (added age-related hypogonadism question); (VLS) 02/2022 (no clinical changes); (MRS) 02/2023 (no clinical changes), 02/2024 (no clinical changes), 02/2025 (no clinical changes)

Reviewed: CDPR/Medical Affairs (MM): 01/2005, 02/2006; (WF): 02/2007, 01/2008, 12/2008, 11/2009; (KP) 11/2010, 11/2011, 03/2012, 10/2012; (DNC) 11/2012; (LCB) 11/2013; (SES) 11/2014; (KRU) 02/2015; (LCB) 11/2015; (ME) 11/2016, 02/2017, 11/2017, 10/2018; (EPA) 08/2019; (CHART) 10/31/19, 02/27/20, 02/25/21, 02/24/2022, 03/02/2023, 02/29/2024, 02/27/2025

External Review: 08/2005, 04/2006, 06/2007, 04/2008, 04/2009, 02/2010, 02/2011, 03/2012, 02/2013, 02/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019, 10/2019 (FYI), 02/2020, 06/2020, 06/2021, 06/2022, 06/2023, 06/2024, 06/2025

CRITERIA FOR APPROVAL

- | | | | |
|---|--|-----|----|
| 1 | Is the requested drug being prescribed for age-related hypogonadism (also referred to as late-onset hypogonadism)? [Safety and efficacy of testosterone in patients with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.]
[If Yes, then no further questions. If No, then go to 2.] | Yes | No |
| 2 | Is the requested drug being prescribed for primary or hypogonadotropic hypogonadism?
[If Yes, then go to 3. If No, then go to 6.] | Yes | No |

3	Is this request for continuation of therapy? [If Yes, then go to 4. If No, then go to 5.]	Yes	No
4	Before the patient started testosterone therapy, did the patient have a confirmed low morning testosterone level according to current practice guidelines or your standard lab reference values? [No further questions]	Yes	No
5	Does the patient have at least TWO confirmed low morning testosterone levels according to current practice guidelines or your standard lab reference values, before the start of testosterone therapy? [No further questions]	Yes	No
6	Is this request for intramuscular testosterone enanthate injection (generic Delatestryl)? [If Yes, then go to 7. If No, then no further questions.]	Yes	No
7	Is the requested drug being prescribed for inoperable metastatic breast cancer in a patient who is 1 to 5 years postmenopausal AND had an incomplete response to other therapy for metastatic breast cancer? [If Yes, then no further questions. If No, then go to 8.]	Yes	No
8	Is the requested drug being prescribed for a premenopausal patient with breast cancer who has benefited from oophorectomy AND is considered to have a hormone-responsive tumor? [If Yes, then no further questions. If No, then go to 9.]	Yes	No
9	Is the requested drug being prescribed for delayed puberty? [No further questions]	Yes	No

Mapping Instructions			
	Yes	No	DENIAL REASONS
1.	Deny	Go to 2	We have denied your request because your plan does not cover this drug for age-related hypogonadism, also referred to as late-onset hypogonadism. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.

			[Short Description: Exclusion, age-related hypogonadism]
2.	Go to 3	Go to 6	
3.	Go to 4	Go to 5	
4.	Approve, 12 Months	Deny	<p>Your plan only covers this drug when you had a morning testosterone test before you started testosterone treatment and your test results were in a certain range (low). We denied your request because: A) You did not have a morning testosterone test before you started treatment, or B) Your results were not in the approvable range. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Continuation, lab/test]</p>
5.	Approve, 12 Months	Deny	<p>Your plan only covers this drug when you have had two morning testosterone tests before starting treatment and your test results are in a certain range (low). We denied your request because: A) You did not have two morning testosterone tests before starting treatment, or B) Your results were not in the approvable range. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Lab/test]</p>
6.	Go to 7	Deny	<p>Your plan only covers this drug when it is used for certain health conditions. Covered uses are primary hypogonadism and hypogonadotropic hypogonadism. Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been</p>

			<p>denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Diagnosis, Xyosted]</p>
7.	Approve, 12 Months	Go to 8	
8.	Approve, 12 Months	Go to 9	
9.	Approve, 12 Months	Deny	<p>Your plan only covers this drug when it is used for certain health conditions. Covered uses are: A) Primary hypogonadism, B) Hypogonadotropic hypogonadism, C) Breast cancer in specific situations, and D) Delayed puberty. Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Diagnosis, generic Delatestryl]</p>